@article{ref1,
title="Worsening anxiety and depression after initiation of lumacaftor/ivacaftor combination therapy in adolescent females with cystic fibrosis",
journal="Journal of cystic fibrosis",
year="2017",
author="McKinzie, Cameron J. and Goralski, Jennifer L. and Noah, Terry L. and Retsch-Bogart, George Z. and Prieur, Mary Beth",
volume="16",
number="4",
pages="525-527",
abstract="In both phase III studies of LUM/IVA, as well as an extension study, worsening of mental health was not reported as a common side effect. Here we describe five cases in adolescent female patients that suggest a worsening of anxiety or depression associated with its use. In these five patients, two experienced suicidal ideation and three made suicide attempts that resulted in psychiatric hospitalizations.<p /><p>Language: en</p>",
language="en",
issn="1569-1993",
doi="10.1016/j.jcf.2017.05.008",
url="http://dx.doi.org/10.1016/j.jcf.2017.05.008"
}